top of page
Inkomstrapporter

FROSTPHARMA MAGAZINE

For News and Media

FrostPharma receives the distribution rights for Efmody® in the Nordics in May 2024

Press release, May 2024


FrostPharma was founded late 2016 and have since grown significantly, the vision is to become a leading specialty pharma company. We are now happy to announce that FrostPharma take another step towards their vision by receiving the distribution rights from Diurnal Limited, a Neurocrine Biosciences company, in the Nordics for Efmody® (hydrocortisone modified-release hard capsules). Efmody is the second endocrinology product in addition to Alkindi (hydrocortisone granules in capsules for opening) that FrostPharma distribute in the Nordics.


Efmody® (hydrocortisone modified-release hard capsules) provides a treatment option for adult and adolescent patients suffering from the rare condition congenital adrenal hyperplasia (CAH). CAH is caused by deficiency of adrenal enzymes, most commonly 21-hydroxylase. Approximately two-thirds of CAH patients are estimated to have poor disease control, leading to elevated androgen levels.


Alkindi® (hydrocortisone modified-release hard capsules) is designed for children suffering from adrenal congenital insufficiency and allows for age-appropriate dosing in children. This therapeutic approach has the potential to help young patients less than eighteen years of age.


With the addition of Efmody® in the FrostPharma portfolio we have now a broader range of opportunities to provide treatments for patients in need.



Fredrik Anders, CEO FrostPharma


“We are very proud of our cooperation with Diurnal, that we now expand to include Efmody. Efmody has excellent strategic fit with Alkindi and fit well with the FrostPharma business model of providing niched hospital pharmaceuticals within areas of identified unmet needs."




Contact

For further information please contact

Fredrik Andersch, CEO FrostPharma Fredrik.andersch@frostphama.com

Rebecka Grund, COO FrostPharma rebecka.grund@frostpharma.com





More information


Congenital Adrenal Hyperplasia (CAH)

Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal hormones which are essential for life. Approximately 95% of CAH cases are caused by a mutation that leads to deficiency of the enzyme 21-hydroxylase (21-OHD). Severe deficiency of this enzyme leads to an inability of the adrenal glands to produce cortisol and, in approximately 75% of cases, aldosterone. If left untreated, CAH can result in salt wasting, dehydration, and even death.


Efmody®

Efmody® (hydrocortisone modified-release hard capsules) is a preparation of hydrocortisone that has been specifically designed to mimic the circadian rhythm of cortisol when given in a twice-a-day "toothbrush" regimen (administered last thing at night before sleep and first thing in the morning on waking) to control androgen excess and chronic fatigue in patients with diseases of cortisol deficiency. The first indication for Efmody® is Congenital Adrenal Hyperplasia (CAH) in adults and adolescents (children older than 12 years of age). Efmody® has been extensively studied in 239 human subjects including 138 CAH patients who have taken part in clinical trials in Europe and the US.


Alkindi®


Alkindi® (hydrocortisone modified-release hard capsules) is a patented, oral, immediate-release paediatric formulation of hydrocortisone granules in capsules for opening that allows for age-appropriate dosing in children. This therapeutic approach has the potential to help young patients less than eighteen years of age suffering from diseases due to cortisol deficiency including paediatric AI and CAH. AI requires life-long treatment and Diurnal’s novel approach to product development has the potential to significantly improve these young patients’ lives.


Diurnal Ltd.


Diurnal Ltd., a Neurocrine Biosciences company, is dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena. Neurocrine Biosciences acquired Diurnal Group plc. in November 2022.


For further information about Diurnal, please visit www.diurnal.co.uk


About FrostPharma


FrostPharma is an entrepreneurial Swedish Specialty Pharma company specializing in the commercialization of value-adding medicines. FrostPharma signed its first product distribution agreement in 2017, and since then +40 products have been added to the therapy agnostic portfolio through a strong agreement deal-flow, as well as through the development of proprietary products. The company has an established specialty pharma platform across the Nordics, and now actively plan to expand to additional EU countries. The FrostPharma portfolio of products are primarily oriented toward hospital use, and hospital initiation. FrostPharma has also developed a separate division offering sustainable solutions to petroleum-based plastics across the Healthcare sector.


For further information please visit frostpharma.com

0 comments

Recent Posts

See All

FrostPharma enters the hematology area in the Nordics

FrostPharma takes another step in its growth journey of becoming a leading European Specialty Pharma company, by being authorized by IDEOGEN as the exclusive Nordic representative to support patient a

Comments


bottom of page